Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
Top Cited Papers
- 31 July 2006
- journal article
- duplicate publication
- Published by Elsevier BV in American Heart Journal
- Vol. 152 (1), 86-92
- https://doi.org/10.1016/j.ahj.2005.06.036
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)American Heart Journal, 2005
- Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in DogsCirculation, 2004
- Role of carvedilol in atrial fibrillation: insights from clinical trialsThe American Journal of Cardiology, 2004
- Characteristics, Outcome, and Care of Stroke Associated With Atrial Fibrillation in EuropeStroke, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Improving survival for patients with atrial fibrillation and advanced heart failureJournal of the American College of Cardiology, 1996
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureThe New England Journal of Medicine, 1996
- Improving survival for patients with advanced heart failure: A study of 737 consecutive patientsJournal of the American College of Cardiology, 1995
- Collagen Metabolism in Cultured Adult Rat Cardiac Fibroblasts: Response to Angiotensin II and AldosteroneJournal of Molecular and Cellular Cardiology, 1994